Clinical trial
A Single-arm, Multicenter, Phase Ib/II Clinical Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-based Therapy
NCT05027204 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Multicenter, Phase Ib/II Clinical Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-based Therapy
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- March 4, 2022
- Completion date
- December 31, 2023
- Enrollment
- 94 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.